1. Home
  2. SNBR vs FHTX Comparison

SNBR vs FHTX Comparison

Compare SNBR & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sleep Number Corporation

SNBR

Sleep Number Corporation

HOLD

Current Price

$8.54

Market Cap

186.9M

ML Signal

HOLD

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

HOLD

Current Price

$5.03

Market Cap

247.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNBR
FHTX
Founded
1987
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
186.9M
247.1M
IPO Year
1998
2020

Fundamental Metrics

Financial Performance
Metric
SNBR
FHTX
Price
$8.54
$5.03
Analyst Decision
Hold
Strong Buy
Analyst Count
3
6
Target Price
$8.00
$11.50
AVG Volume (30 Days)
868.4K
158.2K
Earning Date
11-05-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,440,882,000.00
$24,518,000.00
Revenue This Year
N/A
$47.50
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.49
$2.95
52 Week High
$20.00
$6.79

Technical Indicators

Market Signals
Indicator
SNBR
FHTX
Relative Strength Index (RSI) 72.30 63.06
Support Level $7.63 $4.21
Resistance Level $8.65 $4.59
Average True Range (ATR) 0.76 0.29
MACD 0.22 0.03
Stochastic Oscillator 89.45 78.50

Price Performance

Historical Comparison
SNBR
FHTX

About SNBR Sleep Number Corporation

Sleep Number Corp. is a wellness technology company engaged in the design, manufacturing, marketing and distribution of sleep solutions. The Company generates revenue by marketing and selling its smart beds directly to new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch points including Stores, Online, Phone, and Chat (Total Retail). The products offered by the company are Mattresses, Bedding, Pillows and Furniture.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: